Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations

Executive Summary

Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.

You may also be interested in...



Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M

Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.

Lucentis Fits Genentech’s Small Market/High Need Business Model

The macular degeneration treatment Lucentis (ranibizumab) fits the Genentech business model of developing products for small markets with high unmet medical need, the company said

Lucentis Fits Genentech’s Small Market/High Need Business Model

The macular degeneration treatment Lucentis (ranibizumab) fits the Genentech business model of developing products for small markets with high unmet medical need, the company said

Related Content

UsernamePublicRestriction

Register

PS035485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel